Large-scale clinical trials are essential to validate the prognostic significance of FAP expression levels compared to traditional biomarkers such as ACPA, and to incorporate artificial intelligence-driven tools for PET/CT analysis, which are used to evaluate RA. Here, PRTN3 is linked to rheumatoid arthritis.